Regeneron registers Phase 1b hemodialysis study, Phase 1 Graves' disease trialOct 9Weekly roundup, 6 itemsamrecibartbortezomib
Cadrenal reports FDA alignment on Phase 3 design for HIT drug CAD-1005Aug 31Clinical readoutCadrenal Therapeutics, Inc.
Regeneron registers Phase 1b trial of Factor XI/XII antibodies in dialysis patientsAug 12Trial updateamrecibartcenvacibart